United States-based Signant Health has added Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as clinical vice president, Internal Medicine, it was reported yesterday.
Dr Everhart is to report to the chief medical officer, Dr David Daniel. He is a board-certified in Internal Medicine and a fellow of the American College of Physicians with over 23 years of experience in the practice of medicine and over 12 years of experience in clinical development. Prior to joining Signant, Dr Everhart held positions of vice president, Medical Affairs and vice president, Medical Informatics at Chiltern and Covance, and most recently consulted independently in the areas of Medical Monitoring, Medical Data Review, and Physician Adoption of Technology. He has worked in all phases of clinical development in numerous therapeutic areas including Allergy & Immunology, Cardiovascular, Haematology & Oncology, Infectious Disease & HIV, Neurology, Ophthalmology, Psychiatry, Respiratory, and Rheumatology.
In the new role, Dr Everhart will help accelerate the application of Signant's intelligent eCOA, rater training, predictive analytics and other data quality monitoring products outside of CNS disorders.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA